SH3D21: A Potential Drug Target and Biomarker (G79729)

Target Name: SH3D21

NCBI ID: G79729

SH3D21

SH3D21: A Potential Drug Target and Biomarker

SH3D21, also known as SH3D21 domain containing 21, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and various cellular localizations make it an attractive target for drug development.

The SH3D21 protein is a 21-kDa protein that is expressed in various tissues, including brain, heart, and liver. It is characterized by the presence of a SH3D21 domain, which is a small protein domain that is known for its ability to interact with various cellular signaling pathways. The SH3D21 domain is responsible for the protein's unique structure and function.

One of the key functions of the SH3D21 protein is its role in the regulation of cell adhesion. SH3D21 is involved in the formation of tight junctions, which are a type of cell-cell adhesion that is essential for various physiological processes, including cell signaling and tissue repair.

In addition to its role in cell adhesion, SH3D21 is also involved in the regulation of cell survival. Studies have shown that SH3D21 can inhibit the activity of the oncogenic protein SMAD, which promotes the growth and survival of cancer cells. This suggests that SH3D21 may be an effective target for cancer therapy.

Another potential function of SH3D21 is its role in neurodegenerative diseases. The SH3D21 protein is involved in the regulation of neurotransmitter release from neurons, which is critical for various cognitive and behavioral functions. Studies have shown that SH3D21 is involved in the regulation of dopamine release from neurons, which is a neurotransmitter that is involved in motivation, pleasure, and mood regulation.

In addition to its potential role in neurodegenerative diseases, SH3D21 has also been identified as a potential drug target for various oncogenic diseases, including cancer. The SH3D21 protein is known to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to cancer cells. This suggests that SH3D21 may be an effective target for cancer therapy.

The identification of SH3D21 as a potential drug target and biomarker has led to a growing interest in the development of SH3D21-targeting drugs for various diseases. Studies are currently being conducted to determine the efficacy and safety of SH3D21-targeting drugs in various disease models.

In conclusion, SH3D21 is a protein that has the potential to be a drug target and biomarker for various diseases. Its unique structure and various cellular localizations make it an attractive target for drug development. Further studies are needed to determine the full extent of SH3D21's potential as a drug target and biomarker.

Protein Name: SH3 Domain Containing 21

The "SH3D21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3D21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets